GCTK

Glucotrack, Inc. (GCTK) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Glucotrack, Inc. is a clinical-stage medical device company developing the Glucotrack Continuous Blood Glucose Monitor (CBGM), a fully implantable system designed for a three-year sensor life. The company is currently conducting long-term clinical trials outside the U.S. and preparing for a pre-investigational device exemption (IDE) submission to the FDA, expected in Spring 2026. The company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Capital Structure & Financing: The company raised approximately $13.7 million in the first nine months of 2025. This includes $10.7 million from public equity offerings (ATM and Registered Direct) and $3.0 million from a new promissory note issued in September 2025. The ATM program capacity was fully utilized.
• Stock Splits: The company executed two reverse stock splits in 2025 (1-for-20 in February and 1-for-60 in June). All share data and per-share metrics in this report are retroactively adjusted.
• Derivative Liability Reduction: The derivative liability balance dropped from $17.4 million to $3 thousand due to the cashless exchange of Series B warrants into common stock and the repurchase of Series A warrants.
• Expense Growth: Research and Development (R&D) expenses increased to $8.2 million YTD 2025 from $7.8 million YTD 2024, driven by clinical trial and product development costs. General and Administrative (G&A) expenses rose to $4.0 million YTD 2025 from $2.6 million YTD 2024 due to increased legal and professional fees.
• Net Loss: The YTD net loss increased to $15.8 million from $12.5 million in the prior year, primarily due to higher operating expenses and a $3.3 million charge related to the change in fair value of derivative liabilities.

Outlook, Risks, and Management Commentary

• Clinical Progress: The First-in-Human (FIH) short-term study met all primary and secondary endpoints with a Mean Absolute Relative Difference (MARD) of 7.7%. A long-term clinical study is underway, though protocol amendments are being made to refine participant selection criteria.
• Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern. Current cash of $7.9 million is estimated to be insufficient to fund operations for the next 12 months, with an estimated requirement of $15.0 million.
• Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting, citing inadequate IT controls, insufficient accounting personnel, and lack of segregation of duties. Remediation efforts are ongoing.
• Debt Covenants: The new $3.6 million promissory note requires 100% of net proceeds from a new Equity Line of Credit (ELOC) to be used for repayment until stockholder approval is obtained for the ELOC.

Investor Verification Checklist

• Liquidity Runway: Verify the timeline for the next capital raise given the explicit "substantial doubt" going concern warning and the $7.1 million funding gap for the next 12 months.
• Internal Control Remediation: Monitor progress on fixing material weaknesses in IT and accounting segregation of duties to ensure future financial reporting reliability.
• Clinical Trial Enrollment: Track the status of protocol amendments for the long-term clinical study and the timeline for FDA IDE submission (expected Spring 2026).
• Debt Repayment Terms: Review the terms of the ELOC and the requirement to use 100% of future equity proceeds to repay the September 2025 promissory note.
• Share Count Dilution: Assess the impact of the recent reverse splits and the remaining outstanding warrants (2,507 Series A and 11 Series B) on future dilution.